A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
A phase 3 trial of Imetelstat in myeloproliferative neoplasms, run by Geron Corporation, active and no longer recruiting.
Overview
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment is a phase 3 interventional study registered as NCT04576156 by Geron Corporation, with 327 participants enrolled, started 2021-04-12 and due to reach its primary completion in 2028-06-30. Interventions recorded: Imetelstat and Best Available Therapy (BAT).
Similar pages
not linked directly; found by shared links- TrialStudy to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
Shares Geron Corporation, Imetelstat and the tag pipeline.
- TrialStudy to Assess SLN124 in Patients With Polycythemia Vera
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialA Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialStudy of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialA Study of LY2784544 in Participants With Myeloproliferative Neoplasms
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialExtended Access of Momelotinib in Adults With Myelofibrosis
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialExtension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialINTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.